KalVista Pharmaceuticals (KALV) Profit After Tax Growth (3y) (2019 - 2025)
KalVista Pharmaceuticals (KALV) Profit After Tax Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 9.53% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -27.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 70.25% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -38.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -38.54% |
| Apr 30, 2025 | -26.68% |
| Oct 31, 2024 | -29.09% |
| Jul 31, 2024 | -35.91% |
| Apr 30, 2024 | -45.68% |
| Jan 31, 2024 | -42.14% |
| Oct 31, 2023 | -38.42% |
| Jul 31, 2023 | -32.78% |
| Apr 30, 2023 | -59.31% |
| Jan 31, 2023 | -28.07% |
| Oct 31, 2022 | -55.64% |
| Jul 31, 2022 | -46.44% |
| Apr 30, 2022 | -46.01% |
| Jan 31, 2022 | -78.41% |
| Oct 31, 2021 | -81.18% |
| Jul 31, 2021 | -47.40% |
| Apr 30, 2021 | -180.54% |
| Jan 31, 2021 | -24.28% |
| Oct 31, 2020 | -27.88% |
| Jul 31, 2020 | -29.95% |